CCCC Q3 2021 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+0.6% YoY

Gross Profit

-$16M-185.9% margin

Operating Income

-$24M-285.3% margin

Net Income

-$25M-290.4% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-13.1%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$508M

Total Liabilities

$109M

Stockholders' Equity

$399M

Cash & Equivalents

$163M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+0.6%
Gross Profit	-$16M	$8M	-287.1%
Operating Income	-$24M	-$18M	-32.2%
Net Income	-$25M	-$22M	-13.0%